Document Detail


Therapeutic use of omega-3 fatty acids in bipolar disorder.
MedLine Citation:
PMID:  21721919     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Bipolar disorder (BD) is a severe, chronic affective disorder, associated with significant disability, morbidity and premature mortality. Omega-3 polyunsaturated fatty acids (PUFAs) play several important roles in brain development and functioning. Evidence from animal models of dietary omega-3 (n-3) PUFA deficiency suggest that these fatty acids are relevant to promote brain development and to regulate behavioral and neurochemical aspects related to mood disorders, such as stress responses, depression and aggression, as well as dopaminergic content and function. Preclinical and clinical evidence suggests roles for PUFAs in BD. n-3 PUFAs seem to be an effective adjunctive treatment for unipolar and bipolar depression, but further large-scale, well-controlled trials are needed to examine its clinical utility in BD. The use of n-3 as a mood stabilizer among BD patients is discussed here. This article summarizes the molecular pathways related to the role of n-3 as a neuroprotective and neurogenic agent, with a specific focus on BDNF. It is proposed that the n-3-BDNF association is involved in the pathophysiology of BD and represents a promising target for developing a novel class of rationally devised therapies.
Authors:
Vicent Balanzá-Martínez; Gabriel R Fries; Gabriela D Colpo; Patricia P Silveira; André K Portella; Rafael Tabarés-Seisdedos; Flávio Kapczinski
Related Documents :
25218759 - The role of nmda receptors in the pathophysiology and treatment of mood disorders.
25315819 - Bipolar disorder in women.
11106269 - Genetics of brain development and malformation syndromes.
19779969 - Grandmothers as gems of genetic wisdom: exploring south african traditional beliefs abo...
18257129 - Mitochondrion and its related disorders: making a comeback.
17160339 - Rett syndrome. a review with emphasis on clinical characteristics and intervention.
17107269 - Outcomes to monitor when treating bipolar disorder or schizophrenia.
19119699 - Antibiotics for the allergist: part 1.
25284319 - Case-control genome-wide association study of persistent attention-deficit hyperactivit...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Expert review of neurotherapeutics     Volume:  11     ISSN:  1744-8360     ISO Abbreviation:  Expert Rev Neurother     Publication Date:  2011 Jul 
Date Detail:
Created Date:  2011-07-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101129944     Medline TA:  Expert Rev Neurother     Country:  England    
Other Details:
Languages:  eng     Pagination:  1029-47     Citation Subset:  IM    
Affiliation:
Section of Psychiatry, Department of Medicine, CIBERSAM University of Valencia Medical School, Valencia, Spain; Section of Psychiatry and Psychological Medicine, Department of Medicine, University of Valencia Medical School, CIBERSAM, Avda. Blasco Ibáñez, 15. E46010 Valencia, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Insulin dysfunction and allostatic load in bipolar disorder.
Next Document:  Complementary and alternative medicine therapies in mood disorders.